This study is testing whether an investigational drug called AVTX-009 can reduce painful skin lesions in people with moderate to severe hidradenitis suppurativa (HS). About 250 participants will receive either AVTX-009 or a placebo for 16 weeks to see which is more effective at c…
Phase: PHASE2 • Sponsor: Avalo Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC